Mesa Laboratories (NASDAQ:MLAB) CAO Lyndsey Elizabeth Crennen Sells 118 Shares

Mesa Laboratories, Inc. (NASDAQ:MLAB) CAO Lyndsey Elizabeth Crennen sold 118 shares of Mesa Laboratories stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $101.27, for a total value of $11,949.86. Following the completion of the transaction, the chief accounting officer owned 1,473 shares of the company’s stock, valued at approximately $149,170.71. This represents a 7.42% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Mesa Laboratories Trading Down 4.9%

MLAB traded down $4.85 on Wednesday, hitting $94.84. The company had a trading volume of 154,655 shares, compared to its average volume of 136,917. The company has a market cap of $523.96 million, a PE ratio of 79.03 and a beta of 0.94. Mesa Laboratories, Inc. has a 12-month low of $55.45 and a 12-month high of $113.99. The company has a quick ratio of 1.29, a current ratio of 1.72 and a debt-to-equity ratio of 0.78. The business’s fifty day simple moving average is $101.88 and its 200 day simple moving average is $90.54.

Mesa Laboratories (NASDAQ:MLAB) last released its quarterly earnings results on Wednesday, May 27th. The medical instruments supplier reported $1.53 EPS for the quarter, missing the consensus estimate of $1.78 by ($0.25). The company had revenue of $63.72 million during the quarter, compared to analysts’ expectations of $65.21 million. Mesa Laboratories had a return on equity of 20.96% and a net margin of 2.69%.During the same quarter in the prior year, the business posted ($1.31) EPS.

Mesa Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, June 15th. Investors of record on Friday, May 29th were given a $0.16 dividend. The ex-dividend date was Friday, May 29th. This represents a $0.64 annualized dividend and a yield of 0.7%. Mesa Laboratories’s dividend payout ratio (DPR) is currently 53.33%.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of MLAB. Royal Bank of Canada boosted its position in shares of Mesa Laboratories by 1.2% during the first quarter. Royal Bank of Canada now owns 30,772 shares of the medical instruments supplier’s stock valued at $3,652,000 after buying an additional 353 shares during the period. Jacobs Levy Equity Management Inc. purchased a new position in shares of Mesa Laboratories during the first quarter valued at approximately $335,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Mesa Laboratories by 4.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 3,068 shares of the medical instruments supplier’s stock valued at $364,000 after buying an additional 143 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Mesa Laboratories by 3.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 19,977 shares of the medical instruments supplier’s stock valued at $2,370,000 after buying an additional 685 shares during the period. Finally, American Century Companies Inc. boosted its position in shares of Mesa Laboratories by 1.5% during the second quarter. American Century Companies Inc. now owns 13,431 shares of the medical instruments supplier’s stock valued at $1,265,000 after buying an additional 194 shares during the period. Hedge funds and other institutional investors own 90.60% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings lowered Mesa Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a research report on Wednesday, June 3rd. Two analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Reduce” and a consensus target price of $94.00.

About Mesa Laboratories

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.